Related Experiment Video
Updated: Mar 19, 2026
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
16.6K
Immunological Aspects of Malignant Gliomas
Or Cohen-Inbar1, Menashe Zaaroor1
11Department of Neurological Surgery,Rambam Health Care Center,Haifa,Israel.
Summary
Glioblastoma Multiforme (GBM) remains a deadly brain cancer with poor survival rates due to immune suppression. This review explores GBM immunology and immunotherapy challenges.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Research
Background:
- Glioblastoma Multiforme (GBM) is the most aggressive primary brain tumor.
- Current treatments offer limited survival benefits, with a mean survival time under 24 months.
- GBM's resistance to anti-tumor immunity stems from complex immune-suppressive mechanisms.
Purpose of the Study:
- To review the immunology of Glioblastoma Multiforme.
- To discuss pathological and molecular features contributing to immune evasion.
- To explore current treatment modalities and cancer immunotherapy principles in GBM.
Main Methods:
- Literature review of GBM immunology.
- Analysis of immune-suppressive mechanisms in GBM.
- Discussion of immunotherapy strategies and clinical trials.
Main Results:
- GBM exhibits unique pathological and molecular features enabling immune evasion.
- A complex interplay exists between GBM and the host immune system.
- Immunotherapy faces significant challenges in treating GBM effectively.
Conclusions:
- Understanding GBM immunology is crucial for developing effective treatments.
- Overcoming immune resistance is key to improving patient outcomes.
- Further research into immunotherapy for GBM is warranted.
